Fig. 1: Flow diagram of BCAC patients with primary invasive ER-positive breast cancer, early-stage disease characteristics and AI therapy. | npj Breast Cancer

Fig. 1: Flow diagram of BCAC patients with primary invasive ER-positive breast cancer, early-stage disease characteristics and AI therapy.

From: Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer

Fig. 1: Flow diagram of BCAC patients with primary invasive ER-positive breast cancer, early-stage disease characteristics and AI therapy.The alternative text for this image may have been generated using AI.

The BCAC database (version 12) comprised 92,933 patients with a confirmed diagnosis of invasive ER-positive breast cancer who are of European descent (based on genotype data) and older than or equal to 18 years of age. Of these, 27,887 patients had early-stage disease with documented adjuvant endocrine therapy (AI, Tamoxifen, switch therapy, or unspecified) and complete follow-up data. The subgroup of AI-treated patients analysed in this study comprised 2789 women of which 1335 had received anastrozole, 689 letrozole, and 114 exemestane. For 570 patients, AI treatment was not further specified and 81 patients had received an additional endocrine treatment. AI Aromatase Inhibitor, OS Overall survival, DRFS Distant relapse free survival, RFS Relapse free survival.

Back to article page